[The buyout price is a 54% premium to BSMD’s closing price on Wednesday; news of the deal presumably leaked on Thursday as the share price was up on very high (relative) volume.]
ROCKLAND, Mass.--(BUSINESS WIRE)--BioSphere Medical, Inc. (NASDAQ: BSMD) (“BioSphere Medical” or the “Company”) – the pioneer in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy – today reported that it has entered into an a definitive agreement and plan of merger with Merit Medical Systems, Inc. (NASDAQ: MMSI) and Merit BioAcquisition Co., a wholly-owned subsidiary of Merit Medical pursuant to which BioSphere Medical will merge with and into Merit BioAcquisition Co. in a cash transaction valued at approximately $96 million.
In connection with but prior to the consummation of the transaction, BioSphere Medical intends to call for redemption all 9,636 currently outstanding shares of series A preferred stock at a redemption price of $1,000 per share plus accrued but unpaid dividends. Holders may elect to convert each share of series A preferred stock into 250 shares of common stock prior to consummation of such redemption. Under the terms of the agreement, and assuming the conversion of all outstanding shares of series A preferred stock into shares of common stock, at closing each share of BioSphere Medical common stock will be exchanged for $4.38 per share in cash, representing a premium of approximately 54% over the closing price on May 12, 2010.
David P. Southwell, Chairman of BioSphere Medical, said, “Merit Medical Systems’ strong reputation and experience in interventional radiology and extensive worldwide distribution network make it an ideal fit for BioSphere. This transaction achieves significant value for our shareholders. Furthermore, through Merit, more women suffering from uterine fibroids will benefit from the less invasive treatment solution offered by embolotherapy.”
“We are pleased to bring value to BioSphere shareholders through this planned acquisition. We look forward to effectively integrating into Merit, and we believe that this transaction will allow us to even more fully meet the needs of our customers,” said Richard Faleschini, BioSphere Medical’s president and chief executive officer.
The transaction was unanimously approved on May 13, 2010 by BioSphere Medical’s Board of Directors. Completion of the transaction is subject to approval of BioSphere Medical stockholders, regulatory approvals and other customary closing conditions and is expected to occur early in the third quarter of 2010.
J.P. Morgan Securities Inc. is acting as financial advisor, and WilmerHale LLP is acting as legal counsel, to BioSphere Medical.
…About BioSphere Medical, Inc.
BioSphere Medical, Inc. seeks to pioneer and commercialize minimally invasive diagnostic and therapeutic applications based on proprietary bioengineered microsphere technology. The Company’s core technologies, patented bioengineered polymers and manufacturing methods, are used to produce microscopic spherical materials with unique beneficial properties for a variety of medical applications. BioSphere Medical’s principal focus is the use of its products for the treatment of symptomatic uterine fibroids using a procedure called uterine fibroid embolization, or UFE. The Company’s products continue to gain acceptance in this rapidly emerging procedure, as well as in a number of other new and established medical treatments.‹
‡Number is misleading inasmuch as Arius announced in May 2008 that it was pursued by an unnamed suitor.
‡‡Premium relative to commencement of bidding.
‡‡‡To be liquidated by Deerfield following failed merger with Archemix; premium relative to 11/18/08 date of Archemix deal.
‡†Based on closing price 8/21/08, the day before KG announced initial buyout offer.
‡*Based on 11/20/08 close.
†Premium reaches 63% if earn-out met.
††Premium and deal value based on 0.45/sh of contingent payments.
†††Premium relative to 7/30/08 close, the day before BMY announced first buyout offer.
†*Price for 44% of DNA not already owned.
†‡7% discount to market price excludes contingent payments.
*199% premium to volume-weighted price during preceding 3 months.
**Deal value includes assumption of debt.
***Premium and deal value exclude contingent payouts.
*‡Premium relative to 1/26/09, the day before Astellas announced $16/sh offer.
*‡‡Price includes entire deal in three stages; 17% premium is the blended avg price of NVS’ purchases ($164) relative to ACL’s market price 4/4/08 immediately prior to announcement of first stage of deal.
*†Premium includes estimated value of contingent payouts, but listed deal value excludes them.
*††IntelliPharmaCeutics.
*†*Relative to MIL’s price before announcement that co. was for sale.